⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19283148 | 0.93 | ALDH1A1 (0.46) | — | |
| SCHEMBL5546574 | 0.91 | ALDH1A1 (0.50) | — | |
| SCHEMBL5544551 | 0.91 | ALDH1A1 (0.50) | — | |
| SCHEMBL5544701 | 0.91 | ALDH1A1 (0.50) | — | |
| SCHEMBL5543620 | 0.91 | ALDH1A1 (0.50) | — | |
| SCHEMBL5540992 | 0.91 | ALDH1A1 (0.50) | — | |
| SCHEMBL5543586 | 0.91 | ALDH1A1 (0.50) | — | |
| SCHEMBL424385 | 0.84 | — | — | |
| SCHEMBL11154201 | 0.79 | KDM5A (0.33) | — | |
| SCHEMBL5542148 | 0.78 | S1PR2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0998459-A2 | PYRIDINE DERIVATIVES | Novartis AG (CH) | 2000-05-10 | — | — | EP | claimed |
| WO-1999002497-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 1999-01-21 | — | — | WO | claimed |
| EP-0173933-B1 | 1,6-NAPHTHYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENT CONTAINING THEM | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1989-11-29 | — | — | EP | claimed |
| EP-0111455-A2 | Unsaturated lactones | CIBA-GEIGY AG (CH) | 1984-06-20 | — | — | EP | claimed |
| EP-3452465-B1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2020-11-04 | — | — | EP | disclosed |
| US-10577362-B2 | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | GENOSCIENCE PHARMA (FR) | 2020-03-03 | — | — | US | disclosed |
| US-20190144437-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2019-05-16 | — | — | US | disclosed |
| EP-3452465-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | Genoscience Pharma SAS (FR) | 2019-03-13 | — | — | EP | disclosed |
| EP-3071560-B1 | N-ACYLIMINO HETEROCYCLIC COMPOUNDS | BASF SE (DE) | 2018-01-10 | — | — | EP | disclosed |
| WO-2017191599-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2017-11-09 | — | — | WO | disclosed |
| US-9783523-B2 | N-acylimino heterocyclic compounds | BASF SE (DE) | 2017-10-10 | — | — | US | disclosed |
| US-20160297793-A1 | N-ACYLIMINO HETEROCYCLIC COMPOUNDS | BASF SE (DE) | 2016-10-13 | — | — | US | disclosed |
| EP-0171217-A2 | Fused-ring heterocyclic compounds a process for their production and their pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1986-02-12 | — | — | EP | disclosed |
| EP-0165897-A2 | Resorcin ethers | CIBA-GEIGY AG (CH) | 1985-12-27 | — | — | EP | disclosed |
| EP-0145956-A1 | Composés amidés | CIBA-GEIGY AG (CH) | 1985-06-26 | — | — | EP | disclosed |
| US-4497808-A | N-Oxide compounds useful in the treatment of cardiovascular ailments | CIBA-GEIGY CORPORATION (US) | 1985-02-05 | — | — | US | disclosed |
| EP-0111455-A2 | Unsaturated lactones | CIBA-GEIGY AG (CH) | 1984-06-20 | — | — | EP | disclosed |
| EP-0111453-A1 | Amide derivatives | CIBA-GEIGY AG (CH) | 1984-06-20 | — | — | EP | disclosed |
| EP-0089926-A2 | Pharmaceutical preparations of tetracycles containing nitrogen, and compounds of this type | CIBA-GEIGY AG (CH) | 1983-09-28 | — | — | EP | disclosed |
| EP-0083315-A2 | Pyridyl-N-oxides, processes for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1983-07-06 | — | — | EP | disclosed |